4-(溴甲基)苄基氨基甲酸叔丁酯 | 187283-17-6

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(溴甲基)苄基氨基甲酸叔丁酯
• 英文名称: tert-butyl 4-(bromomethyl)benzylcarbamate
• 英文别名: tert-butyl N-[[4-(bromomethyl)phenyl]methyl]carbamate；N-Boc-4-(bromomethyl)benzylamine
• CAS: 187283-17-6
• 化学式: C₁₃H₁₈BrNO₂
• 分子量: 300.195
• InChiKey: UYGBIHFTZHBDEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 4-(bromomethyl)benzylcarbamate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 4-(bromomethyl)benzylcarbamate
CAS number: 187283-17-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H18BrNO2
Molecular weight: 300.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-溴甲基苄基氨基甲酸叔丁酯主要用于作为研究用化合物。

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)苄基氨基甲酸叔丁酯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.25h， 生成 (S)-2-[4-(tert-butoxycarbonylamino-methyl)-benzylamino]-propionic acid cyclopentyl ester
  参考文献：
  名称：

  WO2006/117549

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氨甲基苯甲酸 在 lithium aluminium tetrahydride 、 氢溴酸 、 碳酸氢钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 6.5h， 生成 4-(溴甲基)苄基氨基甲酸叔丁酯
  参考文献：
  名称：

  基于片段增长的潜在客户优化集成策略：以多样性为目标的目标综合方法

  摘要：

  在过去的几十年中，高通量和基于片段的筛选技术的发展极大地促进了命中识别。药物发现中仍然存在的一大障碍是铅对铅（H2L）优化的过程自动化。在这里，我们报告了H2L优化的时间和成本有效的集成策略，以及强力化学探针的部分自动化设计，该技术包括集中化学库设计和虚拟筛选，以及面向机器人多样性的从头合成和自动化体外评估。虚拟库是通过组合一个激活的片段（与绑定到目标的子结构相对应）生成的，从计算机化学相关的一步有机转化清单中精心选择了使用计算机编码的化学反应进行功能化构建的集合。使用溴结构域抑制剂的优化作为测试案例证明了概念验证，从而验证了几种亲和力提高了几个数量级的化合物。

  DOI：

  10.1021/acs.jmedchem.8b00653

文献信息

• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20160235734A1

  公开（公告）日：2016-08-18

  Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

  具有本公式I定义的化合物既作为毒蕈碱受体拮抗剂又作为β2肾上腺素能受体激动剂，并且用于治疗支气管阻塞和炎症性疾病。
• Cryptophycin compounds
  申请人：Eli Lilly and Company

  公开号：US06680311B1

  公开（公告）日：2004-01-20

  The present invention provides cryptophycin compounds of Formula I that are useful in the treatment of neoplasms.

  本发明提供了一种在肿瘤治疗中有用的Formula I的cryptophycin化合物。
• A synthetic method for diversification of the P1′ substituent in phosphinic dipeptides as a tool for exploration of the specificity of the S1′ binding pockets of leucine aminopeptidases
  作者：Stamatia Vassiliou、Metaxia Xeilari、Athanasios Yiotakis、Jolanta Grembecka、Małgorzata Pawełczak、Paweł Kafarski、Artur Mucha

  DOI：10.1016/j.bmc.2007.02.042

  日期：2007.5

  proteolytic enzymes, was elaborated. The procedure was based on parallel derivatization of the amino group in the suitably protected phosphinate building blocks with appropriate alkyl and aryl halides. This synthetic strategy represents an original approach to phosphinic dipeptide chemistry. Its usefulness was confirmed by obtaining a series of P1' modified phosphinic dipeptides, inhibitors of cytosolic leucine

  阐述了一种新的，通用的和通用的使次膦酸盐假二肽中的P1'位置多样化的方法，次膦酸盐假二肽可能是蛋白水解酶的抑制剂。该程序基于适当保护的次膦酸酯结构单元中的氨基与适当的烷基和芳基卤化物平行衍生而来。这种合成策略代表了次膦酸二肽化学的原始方法。通过基于结合在酶活性中的高苯丙氨酰基-苯丙氨酸类似物（hPheP [CH（2）] Phe）的结构的计算机辅助设计，获得了一系列P1'修饰的次膦酸二肽（胞质亮氨酸氨基肽酶的抑制剂），证实了其有用性。网站作为主导结构。在这种方法中，抑制剂P1'片段与酶的S1'区之间存在新颖的相互作用，尤其是涉及Asn330和Asp332酶残基的氢键被预测。讨论了对胞质亮氨酸氨基肽酶和氨基肽酶N的设计，合成和活性评估的细节。尽管先导化合物的效力没有提高，但是观察到合成抑制剂对两种研究的酶的显着选择性。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。